Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences announced steady progress in Q1 2026, completing Phase 1b studies for two herpesvirus drug candidates, completing toxicology studies for a hepatitis delta virus candidate, and preparing for a Phase 2 initiation later in 2026. The company also reported a strong cash position projected to fund operations into 2028, despite a net …